Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which score best predicts danger in upper GI bleeding?

NCT ID NCT07819942

Diagnosis Sponsor: Kathmandu Medical College and Teaching Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers compare three scoring tools, the Glasgow-Blatchford Score, AIMS65, and pre-endoscopic Rockall Score, to see which best predicts outcomes for patients with upper gastrointestinal bleeding. The study enrolls about 100 patients aged 16 and older who arrive with signs such as vomiting blood or black stools. Doctors collect clinical and lab data during the hospital stay and track events like blood transfusion within 24 hours, ICU admission, rebleeding, and early death. The goal is to learn which score most accurately flags patients at risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If one score proves more accurate, doctors could use it to quickly identify which patients with upper gastrointestinal bleeding need urgent transfusion, intensive care, or closer monitoring.
What could go wrong
This is a small observational study at a single hospital, so the results may not apply to other settings or patient groups. The scores are compared only for prediction, not for improving outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Feb 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients (≥16 years) presenting with signs and symptoms of acute upper gastrointestinal bleeding- hematemesis, melena, or hematochezia-at the Emergency Department or Gastroenterology Unit.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥16 years. * Presenting with acute UGIB (hematemesis, melena, or hematochezia). * Patients providing informed written consent. Exclusion Criteria: * Patients with lower gastrointestinal bleeding or uncertain source of bleeding. * Patients with prior UGIB within the last 30 days. * Patients refusing consent. * Patients who are lost to follow-up before assessment of primary outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ugi bleed are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gastrointestinal Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ugi bleed

Contacts and locations

Locations

  • Kathmandu Medical College and Teaching Hospital

    Kathmandu, Bagmati, 44600, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.